Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adlai Nortye Ltd ANL

Healthcare Biotechnology
Adlai Nortye Ltd is a Cayman Island-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of cancer therapies. The Company’s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is... see more

Recent & Breaking News (NDAQ:ANL)

    Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress

    GlobeNewswire August 8, 2024

    Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

    GlobeNewswire August 8, 2024

    Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

    GlobeNewswire May 23, 2024

    Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

    GlobeNewswire May 22, 2024

    Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

    GlobeNewswire March 29, 2024

    Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

    GlobeNewswire November 17, 2023

    Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

    GlobeNewswire October 23, 2023

    Adlai Nortye Ltd. Announces Closing of Initial Public Offering

    GlobeNewswire October 3, 2023

    Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

    GlobeNewswire September 29, 2023